Verdinexor targeting of CRM1 is a promising therapeutic approach against RSV and influenza viruses

Jennifer A. Pickens, Ralph A. Tripp

Research output: Contribution to journalReview articlepeer-review

21 Citations (Scopus)
16 Downloads (Pure)


Two primary causes of respiratory tract infections are respiratory syncytial virus (RSV) and influenza viruses, both of which remain major public health concerns. There are a limited number of antiviral drugs available for the treatment of RSV and influenza, each having limited effectiveness and each driving selective pressure for the emergence of drug-resistant viruses. Novel broad-spectrum antivirals are needed to circumvent problems with current disease intervention strategies, while improving the cytokine-induced immunopathology associated with RSV and influenza infections. In this review, we examine the use of Verdinexor (KPT-335, a novel orally bioavailable drug that functions as a selective inhibitor of nuclear export, SINE), as an antiviral with multifaceted therapeutic potential. KPT-335 works to (1) block CRM1 (i.e., Chromosome Region Maintenance 1; exportin 1 or XPO1) mediated export of viral proteins critical for RSV and influenza pathogenesis; and (2) repress nuclear factor κB (NF-κB) activation, thus reducing cytokine production and eliminating virus-associated immunopathology. The repurposing of SINE compounds as antivirals shows promise not only against RSV and influenza virus but also against other viruses that exploit the nucleus as part of their viral life cycle.

Original languageEnglish
Article number48
Pages (from-to)1-24
Number of pages24
Issue number1
Publication statusPublished - 21 Jan 2018
Externally publishedYes


Dive into the research topics of 'Verdinexor targeting of CRM1 is a promising therapeutic approach against RSV and influenza viruses'. Together they form a unique fingerprint.

Cite this